phosphorus has been researched along with Hematologic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shanholtz, CB; Thompson, JL; Vines, AN | 1 |
| Chang, H; Jou, ST; Liang, DC; Lin, KH; Lin, SF; Shih, LY; Wang, LY; Yeh, TC | 1 |
| BERNHARD, A; EICHEN, S; ROSENBLOOM, L | 1 |
1 trial(s) available for phosphorus and Hematologic Neoplasms
| Article | Year |
|---|---|
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calcium; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Injections, Intravenous; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Phosphorus; Potassium; Risk Factors; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2006 |
2 other study(ies) available for phosphorus and Hematologic Neoplasms
| Article | Year |
|---|---|
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gout Suppressants; Hematologic Neoplasms; Humans; Hyperuricemia; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Phosphorus; Practice Guidelines as Topic; Retrospective Studies; Risk Factors; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2010 |
A study of inorganic phosphorus release accompanying glycolysis of blood in cancer.
Topics: Glycolysis; Hematologic Neoplasms; Humans; Neoplasms; Phosphorus | 1948 |